PDF icon PDF herunterladen
Semin Liver Dis 2017; 37(04): 305-313
DOI: 10.1055/s-0037-1608655
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Timing, Management, and Outcomes of Liver Transplantation in Primary Sclerosing Cholangitis

Eric F. Martin
1   Department of Medicine, Miami Transplant Institute, Miami, Florida
2   Division of Hepatology, Miller School of Medicine, University of Miami, Miami, Florida
,
Cynthia Levy
2   Division of Hepatology, Miller School of Medicine, University of Miami, Miami, Florida
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
22. Dezember 2017 (online)

   Lizenzen und Reprints
Preview

Abstract

Primary sclerosing cholangitis (PSC) is a chronic, immune-mediated cholestatic liver disease that often progresses to secondary biliary cirrhosis and end-stage liver disease. Short of liver transplantation (LT), there is no effective treatment for PSC. PSC accounts for approximately 5% of total adult LTs in the US and is currently the fifth most common indication for LT. Patient and graft survival for PSC is among the highest for all indications for LT. The main factors that impact outcomes after LT for PSC include biliary strictures, rejection, and recurrence of PSC. Recurrent PSC (rPSC) develops in 20% of LT recipients within 5 years of LT and is associated with negative patient and graft survival. LT is a viable option for recipients who develop rPSC and progress to graft failure.

Keywords

primary sclerosing cholangitis - liver transplantation - recurrence - outcomes